The Non-Malignant Channel is supported with funding from Agios (Gold).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2025 | The LUNA4 study: rilzabrutinib in patients with primary ITP after first-line treatment failure
David Kuter, MD, Massachusetts General Hospital, Boston, MA, discusses the LUNA4 study (NCT07007962), a Phase IIIb trial investigating the use of rilzabrutinib, a BTK inhibitor, in patients with primary immune thrombocytopenia (ITP) after first-line treatment failure. The goal of the study is to improve platelet count and quality of life, and to potentially alter the disease trajectory through early intervention. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
